In 2011, ruxolitinib was the first JAK inhibitor approved for the treatment of myelofibrosis (MF), a myeloproliferative neoplasm (MPN) that harbors a high frequency of the recurrent activating JAK2 p. V617F point mutation. The gene discussed is JAK2; the disease is myeloproliferative disorder.